Serum amyloid A augments the atherogenic effects of cholesteryl ester transfer protein
Journal of Lipid Research · 2023
DOI: 10.1016/j.jlr.2023.100365 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Lipid Research, 2023. Verfasst von Ailing Ji und 6 weiteren Autor:innen. Beteiligte Einrichtung: Barnstable Brown Diabetes Center, University of Kentucky, Lexington, KY, USA; Saha Cardiovascular Research Center, University of Kentucky, Lexington,…. Hauptthemen laut MEDLINE: Cholesterol Ester Transfer Proteins, Atherosclerosis. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, NIDDK NIH HHS, BLRD VA.
Abstract (Originalsprache)
Serum amyloid A (SAA) is predictive of CVD in humans and causes atherosclerosis in mice. SAA has many proatherogenic effects in vitro. However, HDL, the major carrier of SAA in the circulation, masks these effects. The remodeling of HDL by cholesteryl ester transfer protein (CETP) liberates SAA restoring its proinflammatory activity. Here, we investigated whether deficiency of SAA suppresses the previously described proatherogenic effect of CETP. ApoE-/- mice and apoE-/- mice deficient in the three acute-phase isoforms of SAA (SAA1.1, SAA2.1, and SAA3; "apoE-/- SAA-TKO") with and without adeno-associated virus-mediated expression of CETP were studied. There was no effect of CETP expression or SAA genotype on plasma lipids or inflammatory markers. Atherosclerotic lesion area in the aortic arch of apoE-/- mice was 5.9 ± 1.2%; CETP expression significantly increased atherosclerosis in apoE-/- mice (13.1 ± 2.2%). However, atherosclerotic lesion area in the aortic arch of apoE-/- SAA-TKO mice (5.1 ± 1.1%) was not significantly increased by CETP expression (6.2 ± 0.9%). The increased atherosclerosis in apoE-/- mice expressing CETP was associated with markedly increased SAA immunostaining in aortic root sections. Thus, SAA augments the atherogenic effects of CETP, which suggests that inhibiting CETP may be of particular benefit in patients with high SAA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Barnstable Brown Diabetes Center, University of Kentucky, Lexington, KY, USA; Saha Cardiovascular Research Center, University of Kentucky, Lexington, KY, USA.
- Barnstable Brown Diabetes Center, University of Kentucky, Lexington, KY, USA; Saha Cardiovascular Research Center, University of Kentucky, Lexington, KY, USA; Department of Internal Medicine, University of Kentucky, Lex…
- Barnstable Brown Diabetes Center, University of Kentucky, Lexington, KY, USA; Saha Cardiovascular Research Center, University of Kentucky, Lexington, KY, USA; Department of Pharmacology and Nutritional Sciences, Univers…
Förderung
- NIGMS NIH HHS
- NIDDK NIH HHS
- BLRD VA
- NHLBI NIH HHS
- National Institutes of Health
- National Institute of General Medical Sciences
- U.S. Department of Veterans Affairs
Zitieren
APA
Ji, A., Trumbauer, A. C., Noffsinger, V. P., de Beer, F. C., Webb, N. R., Tannock, L. R., & Shridas, P. (2023). Serum amyloid A augments the atherogenic effects of cholesteryl ester transfer protein. Journal of Lipid Research. https://doi.org/10.1016/j.jlr.2023.100365
Vancouver
Ji A, Trumbauer AC, Noffsinger VP, de Beer FC, Webb NR, Tannock LR, et al. Serum amyloid A augments the atherogenic effects of cholesteryl ester transfer protein. Journal of Lipid Research. 2023. doi:10.1016/j.jlr.2023.100365
BibTeX
@article{Ji2023,
author = {Ji, Ailing and Trumbauer, Andrea C and Noffsinger, Victoria P and de Beer, Frederick C and Webb, Nancy R and Tannock, Lisa R and Shridas, Preetha},
title = {Serum amyloid A augments the atherogenic effects of cholesteryl ester transfer protein},
journal = {Journal of Lipid Research},
year = {2023},
doi = {10.1016/j.jlr.2023.100365}
}
EUVIMED